Table 1.
Demographics and clinical characteristics of patients in BRASS using a TNF inhibitor.
| Patients Not Using a TNF Inhibitor* | Patients Using a TNF Inhibitor* | p | |
|---|---|---|---|
| No. of patients | 419 | 503 | |
| Age, yrs | 59.3 ± 14.2 | 55.4 ± 13.5 | < 0.0001 |
| Gender female (%) | 333 (79) | 427 (85) | 0.03 |
| Disease duration, yrs | 13.5 ± 12.6 | 14.7 ± 12.3 | 0.17 |
| Rheumatoid factor-positive (%) | 199 (48) | 336 (67) | < 0.0001 |
| Anti-CCP antibody-positive (%) | 216 (52) | 356 (71) | < 0.0001 |
| Presence of nodules (%) | 108 (26) | 215 (43) | < 0.0001 |
| Prior use of synthetic DMARD (%) | 243 (58) | 381 (76) | < 0.0001 |
| No. of prior synthetic DMARD, mean ± SD | 1.1 ± 1.2 | 1.9 ± 1.6 | < 0.0001 |
| Prior use of TNF inhibitor (%) | 38 (9) | 101 (20) | < 0.0001 |
| Concomitant use of prednisone (%) | 116 (28) | 183 (36) | 0.005 |
| Concomitant use of methotrexate (%) | 184 (44) | 237 (47) | 0.33 |
| Concomitant use of NSAID (%) | 208 (50) | 250 (50) | 0.99 |
| RADAI | 3.3 ± 2.2 | 3.7 ± 2.3 | 0.01 |
| DAS28-CRP3 | 3.9 ± 1.5 | 4.2 ± 1.6 | 0.003 |
| MD-HAQ | 0.6 ± 0.5 | 0.7 ± 0.5 | 0.001 |
*
Number of patients (%) unless otherwise noted.